Fiche société
Bastyr University
Traitements, essais et publications liés.
Traitements3programmes
Essais1liés
Publications6liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Intranasal glutathione - (in)GSHExcessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of Parkinson's disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility of this therapy. Intranasal GSH, (in)GSH, is a novel method of delivery for this popular CAM therapy in patients with PD, and bypasses the obstacles associated with other delivery methods. It has been used in clinical practice since 2005. The aim of this study is to evaluate safety, tolerability, and preliminary absorption data of (in)GSH in volunteers with PD in a Phase I single ascending dose escalation study. | Parkinson | Phase 1 | Traitement symptomatique | United States | À vérifier |
| Saline Intranasal DeliveryExcessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of Parkinson's disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility of this therapy. Intranasal GSH, (in)GSH, is a novel method of delivery for this popular CAM therapy in patients with PD, and bypasses the obstacles associated with other delivery methods. It has been used in clinical practice since 2005. The aim of this study is to evaluate safety, tolerability, and preliminary absorption data of (in)GSH in volunteers with PD in a Phase I single ascending dose escalation study. | Parkinson | Phase 1 | Traitement symptomatique | United States | À vérifier |
| Intranasal glutathione - (in)GSHExcessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of Parkinson's disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility of this therapy. Intranasal GSH, (in)GSH, is a novel method of delivery for this popular CAM therapy in patients with PD, and bypasses the obstacles associated with other delivery methods. It has been used in clinical practice since 2005. The aim of this study is to evaluate safety, tolerability, and preliminary absorption data of (in)GSH in volunteers with PD in a Phase I single ascending dose escalation study. | Parkinson | Phase 1 | Traitement symptomatique | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Intranasal glutathione - (in)GSH | Parkinson | Phase 1 | NCT01398748 | Intranasal Glutathione in Parkinson's Disease | COMPLETED |
Publications
6| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Saline Intranasal Delivery | Revisited case for intranasal neuropeptide Y based therapeutics: From preclinical to clinical. | Neuropeptides | ||
| Intranasal glutathione - (in)GSH | Safety survey of intranasal glutathione. | Journal of alternative and complementary medicine (New York, N.Y.) | ||
| Saline Intranasal Delivery | Smell and the sinuses. | Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | ||
| Saline Intranasal Delivery | Mesenchymal stem cell secretome attenuates disease-associated microglial activation and cognitive decline in TBI-associated neuroinflammation. | Neurochemistry international | ||
| Intranasal glutathione - (in)GSH | Central nervous system uptake of intranasal glutathione in Parkinson's disease. | NPJ Parkinson's disease | ||
| Intranasal glutathione - (in)GSH | Phase IIb Study of Intranasal Glutathione in Parkinson's Disease. | Journal of Parkinson's disease |